DRIZALMA SPRINKLE (duloxetine) by Fosun Pharma is antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the cns. First approved in 2019.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
DRIZALMA SPRINKLE is a delayed-release oral capsule formulation of duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) approved in 2019. It treats depression, anxiety, chronic pain, and fibromyalgia by potentiating serotonergic and noradrenergic activity in the central nervous system. The sprinkle formulation allows flexible dosing via capsule opening and pellet dispersion.
Peak-stage small molecule with modest Part D penetration (35K claims, $9K spending in 2023) signals a specialized or niche market position requiring focused medical and sales strategy within a lean team structure.
antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta
A Study Of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta Under Fed Conditions
A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder
Worked on DRIZALMA SPRINKLE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moDRIZALMA SPRINKLE roles focus on commercial execution and market access in a mature, competitive antidepressant landscape with modest uptake. Career growth is constrained by limited clinical pipeline and small patient base (35K Part D claims), favoring specialists in reimbursement, payer relations, and niche market positioning.